- IN₹366.20m
- IN₹533.25m
- IN₹520.81m
- 69
- 40
- 42
- 49
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.1 | ||
| Price to Tang. Book | 1.1 | ||
| Price to Free Cashflow | 71.41 | ||
| Price to Sales | 0.88 | ||
| EV to EBITDA | 11.44 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 8.31% | ||
| Return on Equity | 3.15% | ||
| Operating Margin | 7.62% | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 480.77 | 513.39 | 513.57 | 589.56 | 520.81 | n/a | n/a | 0.11% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +25.53 | -27.47 | +23.16 | +294.33 | -41.98 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Concord Drugs Limited is an India-based pharmaceutical company. The principal activity of the Company is to manufacture licensed drugs based on the formulations approved. The Company offers finished pharmaceutical formulations, such as injectables (small volume parenteral, dry powders), tissue bio-adhesive, tablets, capsules, liquid orals (syrup and suspension) and dry syrups (powder). The Company also provides ready-to-fill pellets and multiple unit pellet system (MUPS). Its injectables include Amikacin Injection, Aceclofenac Injection, Artemether Injection, Adenosine Injection, and others. Iso Amyl 2-Cyano Acrylate is a tissue bio-adhesive. Its pellets are categorized as gastrointestinal drug pellets, cardiovascular drug pellets, respiratory drug pellets, anti-obesity drug pellets, anti-depressant drug pellets, central nervous system drug pellets, urological drug pellets, anti-microbial, anti-infective and adjuvant drugs pellets, taste mask drug pellets/powder, and others.
Directors
- Seelam Reddy CHM (52)
- Seelam Reddy CFO (32)
- Jyoti Goyal CCO
- S. Manoj Reddy EDR (31)
- S. Hareesh NID (30)
- P. Kala NID
- K. Reddy NID
- Last Annual
- March 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 24th, 1995
- Public Since
- February 23rd, 2015
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Bombay Stock Exchange- Shares in Issue
- 10,000,000
- Address
- Survey No: 249, Brahmanapally(V), Hayath, HYDERABAD, 501511
- Web
- https://concorddrugs.in/
- Phone
- +91 9052779505
- Auditors
- N G Rao & Associates
Upcoming Events for 538965
Similar to 538965
Achyut Healthcare
Bombay Stock Exchange
Adline Chem Lab
Bombay Stock Exchange
MPS Pharmaa
Bombay Stock Exchange
Albert David
Bombay Stock Exchange
Ambalal Sarabhai Enterprises
Bombay Stock Exchange
FAQ
As of Today at 19:06 UTC, shares in CONCORD DRUGS are trading at IN₹36.62. This share price information is delayed by 15 minutes.
Shares in CONCORD DRUGS last closed at IN₹36.62 and the price had moved by +26.28% over the past 365 days. In terms of relative price strength the CONCORD DRUGS share price has underperformed the S&P BSE 100 Index by -3% over the past year.
There is no consensus recommendation for this security.
CONCORD DRUGS does not currently pay a dividend.
CONCORD DRUGS does not currently pay a dividend.
CONCORD DRUGS does not currently pay a dividend.
To buy shares in CONCORD DRUGS you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of IN₹36.62, shares in CONCORD DRUGS had a market capitalisation of IN₹366.20m.
Here are the trading details for CONCORD DRUGS:
- Country of listing: India
- Exchange: BSE
- Ticker Symbol: 538965
Based on an overall assessment of its quality, value and momentum CONCORD DRUGS is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CONCORD DRUGS. Over the past six months, its share price has underperformed the S&P BSE 100 Index by -12.42%.
As of the last closing price of IN₹36.62, shares in CONCORD DRUGS were trading -2.16% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The CONCORD DRUGS PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹36.62.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
CONCORD DRUGS' management team is headed by:
- Seelam Reddy - CHM
- Seelam Reddy - CFO
- Jyoti Goyal - CCO
- S. Manoj Reddy - EDR
- S. Hareesh - NID
- P. Kala - NID
- K. Reddy - NID